This post was written by Paul Sheives. FDA will hold a 2-day public meeting on July 27 and 28, 2010 to address the development and implementation of risk evaluation and mitigation strategies (REMS) for drugs and biological products. The purpose of the meeting is to seek public input on various concerns that stakeholders have raised on the impact of REMS throughout the health care system. Registration for the meeting closes July 6, 2010. FDA also seeks input on the draft guidance entitled ‘‘Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications’’ (released in October, 2009). The comment period for the draft guidance has been reopened; FDA will accept comments until August 31, 2010.